Publications

Alban J, Bowen RC, Reichstein DA, McKean M, Lutzky J, Weis E, Carvajal RD, Dulka S, Morse BG, Butler MO, Rapisuwon S, Kim KB, Chandrasekaran S, Warner AB, Zager JS, Chmielowski B, Patel SP, Hernandez-Aya LF, Correa ZM, Fecher LA, Najjar YG, Montazeri K, Shoushtari AN, Javed A, Gombos DS, Salama AKS, Tsai K, Miller FH, Khushalani N, Seedor RS, Lipson EJ, Reddy SA, Buchbinder E, Bhatia S, Pavlick A, Mehmi I, Aaberg T, Ikeguchi AP, Kim IK, Walter SD, Singh AD, Sullivan RJ, Choi JS, Williams BK, Orloff M, Mruthyunjaya P, Schollenberger MD, Gandhi N, Harbour JW, Chandra S. Metastatic Uveal Melanoma Surveillance: A Delphi Panel Consensus. Cancers. 2025. PMID: 41514630

Kim J, Correy GJ, Hall BW, Rachman MM, Mailhot O, Togo T, Gonciarz RL, Jaishankar P, Neitz RJ, Hantz ER, Doruk YU, Stevens MGV, Diolaiti ME, Reid R, Gopalkrishnan S, Krogan NJ, Renslo AR, Ashworth A, Shoichet BK, Fraser JS. Large scale prospective evaluation of co-folding across 557 Mac1-ligand complexes and three virtual screens. bioRxiv : the preprint server for biology. 2025. PMID: 41509292

Park YH, Cortes J, Modi S, Hurvitz SA, Bianchini G, Iwata H, Shitara K, Siena S, Goto Y, Ku GY, Powell CA, Swain SM, Arunachalam M, Janek M, Cheng Y, Chu C, Verma P, Kuptsova-Clarkson N, Mathias E, Goodman E, Rugo HS. Characterization of the safety profile of trastuzumab deruxtecan by dose: a pooled analysis across DESTINY studies. The oncologist. 2025. PMID: 41330717

Pistilli B, Jhaveri K, Im SA, Pernas S, De Laurentiis M, Wang S, Martínez Jañez N, Borges G, Cescon DW, Hattori M, Lu YS, Hamilton E, Tsurutani J, Kalinsky K, Rubini Liedke PE, Carroll D, Khan S, Rugo HS, Xu B, Bardia A, TROPION-Breast01 investigators. Datopotamab deruxtecan versus chemotherapy in previously treated inoperable/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 41448362

Seo L, Farran I, Aslam A, Li X, Jaishankar P, Ashworth A, Fraser JS, Renslo AR, Wankowicz SA. Crystallographic Ensembles Reveal the Structural Basis of Binding Entropy in SARS-CoV2 Macrodomain. bioRxiv : the preprint server for biology. 2025. PMID: 41394572

Ashouri K, Millstein J, Yang Y, Xiu J, Soni S, Mittal P, Algaze S, Torres-Gonzalez L, Jayachandran P, Zhang W, Mumenthaler S, Shields AF, Goldberg R, Lou E, Weinberg BA, Graeber TG, Marshall JL, Venook AP, Hoffmann A, Finley SD, Meyer AS, Battaglin F, Lenz HJ. Clinical and molecular characterization of AXL in colorectal cancer, CALGB (Alliance)/SWOG 80405 and real-world data. Journal for immunotherapy of cancer. 2025. PMID: 41423272

Tawagi K, Khaki AR, Chablani PV, Hoffman-Censits J, Koshkin VS, Plimack ER, Galsky MD, Gupta S, Rosenberg JE, Grivas P, O'Donnell PH. Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. Clinical genitourinary cancer. 2025. PMID: 41582039

Chan SL, Kudo M, Sangro B, Kelley RK, Kim JH, Pham B, Hong JY, Waldschmidt DT, Marino D, Joycelyn Lee JX, Gerolami R, Burgoyne AM, Li Q, Nakamura H, Sun P, Baur B, Rimassa L. Early Safety Results from the Phase 3b SIERRA Study of Durvalumab and Tremelimumab as First-Line Treatment for Participants with Unresectable Hepatocellular Carcinoma and a Poor Prognosis. Liver cancer. 2025. PMID: 41585428

Jaishankar P, Correy GJ, Matsui Y, Togo T, Rachman MM, Stevens MGV, Hantz ER, Zheng J, Diolaiti ME, Montano M, Taha TY, Rosecrans J, Pampel J, Krogan NJ, Shoichet BK, Ashworth A, Ott M, Fraser JS, Renslo AR. Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo. Journal of medicinal chemistry. 2025. PMID: 41406955

Roy S, Sun Y, Hussain M, Chi KN, Fizazi K, Davis ID, Halabi S, Agarwal N, Chowdhury S, Tombal B, Morgan SC, Malone S, Barata PC, Ong M, Wallis CJD, Berlin A, Swami U, Kishan AU, Jia AY, Zaorsky NG, Garcia JA, Mendiratta P, Brown JR, Subhash VV, Stockler MR, Thomas H, McKay RR, Small EJ, Shore ND, Saad F, Sweeney CJ, Spratt DE. Early favorable prostate-specific antigen response prediction in metastatic hormone sensitive prostate cancer. Nature communications. 2025. PMID: 41402322

Ayo-Ajibola O, Jung T, Razura DE, Gallagher TJ, Lin ME, Angell TE, Kwon DI. Decreased risk of post-thyroidectomy hypocalcemia with history of GLP-1RA use. Journal of the Endocrine Society. 2025. PMID: 41476725

Huang M, Chen Y, Liang C, Narayan OP, Stallings C, Yu M, Traugot C, Li L, Li K, Vo Q, Wang H, Chou YT, Cech L, Parra D, Garzon L, Parsons D, Diaz E, Zhang C, Mackey C, Sussman H, Zmirska I, Chung M, Zhou C, Glynatsis G, Siemann DW, Licht JD, Li C, Kaye FJ, Xie M, Tan Y, Wu L, Bivona TG, Guan J, Tang X. Drug resistant cancer cells show increased nuclear mechanotransduction and mechanically targetable YAP-regulated vulnerability. Biomaterials. 2025. PMID: 41443038

Nyagabona SK, Haddadi S, Mtei RJ, Sunguya B, Kahesa C, Pallangyo CK, Wang CJ, Van Loon K, Mmbaga EJ. Paving the Way for an Integrated Care Model: Experiences of Women Living With HIV and Breast Cancer in Tanzania. JCO global oncology. 2025. PMID: 41397196

Jung H, Devant P, Ching C, Ota M, Hamilton J, Steinhart Z, Ngo W, Sandoval L, Jung JH, Xu D, An M, Urs E, Chen PA, Allain V, Tada T, Nuñez JK, Landau NR, Liu DR, Eyquem J, Doudna JA, Marson A, Carnevale J. Virus-like particles enable targeted gene engineering and pooled CRISPR screening in primary human myeloid cells. bioRxiv : the preprint server for biology. 2025. PMID: 41415457

Brondfield S, O'Brien B, Rangachari D. Modernizing Medical Education: Educational Strategies to Meet Emerging Needs in Hematology/Oncology. JCO oncology practice. 2025. PMID: 41385759

Loren AW, Lacchetti C, Amant F, Cardonick EH, Carey LA, Christian N, Clark C, Dizon DS, Henry M, Hudson MH, Maués J, Peterson E, Prowell TM, Raab R, Rogers JE, Saeed H, Sekeres MA, Taylor JS, Van Loon K, Wallace WH, Watson KL, Yadav S, Partridge AH. Management of Cancer During Pregnancy: ASCO Guideline. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 41380115

Uwamahoro P, Girukubonye I, Bigirimana JB, Shyirambere C, Van Loon K, Sudore RL, Sanders JJ, Cubaka VK, DeBoer RJ. Correction: Setting the stage for communication skills training in Rwandan cancer care: a qualitative study of local priorities and key contextual factors. BMC palliative care. 2025. PMID: 41372995

Magbanua MJM, Manon NA, Wolf DM, Rivero-Hinojosa S, Ahmed Z, Sayaman RW, Tin A, Renner D, Kalashnikova E, Brown-Swigart L, Hirst GL, Yau C, Li W, Isaacs C, Shatsky RA, Clark AS, Zimmer A, Delson AL, Rodriguez A, Liu MC, Pohlmann PR, Esserman LJ, Rugo HS, DeMichele A, van 't Veer L. Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors. Nature communications. 2025. PMID: 41365872

Kayraklioglu N, Zhang L, Cornelia Ding CK, Greenland NY, Stohr BA, Koshkin VS, Simko JP, Sirohi D. Correlation of Lymphocytic Infiltration and Degree of Pleomorphism with Tumor Mutation Burden in High-Grade Urothelial Carcinoma. Human pathology. 2025. PMID: 41354158

Kilari D, Henderson NC, Yamamoto K, Yao Y, Hwang C, Barata PC, Bilen MA, Graham L, Garje R, Rothstein S, Haider S, Park JJ, Raychaudhuri R, Pilling A, Chin E, Koshkin VS, Tripathi A, Cackowski FC, Nauseef JT, Sokolova A, Ayanambakkam A, Zakharia Y, Schweizer MT, Armstrong AJ, Dorff TB, Reichert ZR, McKay RR. Impact of SPOP Mutations on Clinical Outcomes in Metastatic Prostate Cancer. JCO precision oncology. 2025. PMID: 41348987